Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Direct non-genomic effect of steroid hormones on superoxide anion generation in the bone resorbing osteoclasts.

Berger CE, Horrocks BR, Datta HK.

Mol Cell Endocrinol. 1999 Mar 25;149(1-2):53-9.

PMID:
10375017
2.
3.
4.
5.
6.

Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.

Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.

J Cell Physiol. 2003 Jul;196(1):180-9.

PMID:
12767054
7.

Pertussis toxin inhibits hormonal stimulation of bone resorption in fetal rat limb bones.

Klein RF, Nissenson RA, Strewler GJ.

J Pharmacol Exp Ther. 1991 Sep;258(3):877-81.

PMID:
1653845
8.
9.

Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts.

Lundberg P, Lie A, Bjurholm A, Lehenkari PP, Horton MA, Lerner UH, Ransjö M.

Bone. 2000 Dec;27(6):803-10.

PMID:
11113391
11.
12.

Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor.

Mano M, Arakawa T, Mano H, Nakagawa M, Kaneda T, Kaneko H, Yamada T, Miyata K, Kiyomura H, Kumegawa M, Hakeda Y.

Calcif Tissue Int. 2000 Jul;67(1):85-92.

PMID:
10908419
14.

Vitamin D and bone.

Suda T, Ueno Y, Fujii K, Shinki T.

J Cell Biochem. 2003 Feb 1;88(2):259-66. Review.

PMID:
12520524
15.
16.

Simulation of generation-collection experiments with homogeneous kinetics: application to electrochemical investigation of superoxide radical anion generation by osteoclasts on bone.

Berger CE, Datta HK, Horrocks BR.

Phys Chem Chem Phys. 2011 Mar 28;13(12):5288-97. doi: 10.1039/c0cp02350g. Epub 2011 Jan 31.

PMID:
21279210
17.
18.

Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.

Lossdörfer S, Schwartz Z, Wang L, Lohmann CH, Turner JD, Wieland M, Cochran DL, Boyan BD.

J Biomed Mater Res A. 2004 Sep 1;70(3):361-9.

PMID:
15293309
19.

1,25-Dihydroxy-19-nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro.

Holliday LS, Gluck SL, Slatopolsky E, Brown AJ.

J Am Soc Nephrol. 2000 Oct;11(10):1857-64.

20.

The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.

Kobayashi Y, Ueyama S, Arai Y, Yoshida Y, Kaneda T, Sato T, Shin K, Kumegawa M, Hakeda Y.

J Bone Miner Metab. 2004;22(4):318-28.

PMID:
15221489

Supplemental Content

Support Center